To reveal whether baseline body mass index (BMI), and psychobehavioral and nutritional markers were significant predictors of the change in BMI observed after 4 and 12 months in obese women enrolled in a weight reduction program, including low-energy diet, increased physical activity, cognitive behavior therapy and sibutramine. The impact of changes in psychobehavioral and nutritional markers observed after 4 and 12 months of treatment on BMI changes was also investigated. DESIGN: During a double-blind placebo-controlled 4-month period, subjects received either sibutramine (10 mg/day) or placebo. Then, an open phase with sibutramine administered to all patients continued until month 12. SUBJECTS: In total, 80 obese women (age: 43.9710.6 y, BMI: 36.774.8 kg/m 2 ). MEASUREMENTS: The dependent variable was change in BMI while baseline BMI, mode of treatment, the Beck depression score, the three items (dietary restraint, disinhibition and perceived hunger) of the Eating Inventory (EI), energy and macronutrient intakes were independent variables. At 1-week dietary records were analyzed using a computer software for assessing energy and macronutrient intake. RESULTS: Multiple regression analysis revealed that the BMI loss at month 4 was significantly influenced by mode of treatment and initial BMI, whereas a borderline negative relationship was observed with the baseline restraint score. Baseline BMI, depression score, restraint score and total energy intake predicted weight loss at month 12. These predictive variables accounted for 43.8% of the variance in BMI loss at 12 months. When relationships between the BMI loss and changes in all included psychobehavioral and nutritional parameters were considered after 12 months of treatment, a drop in the disinhibition score of the EI appeared the only significant factor affecting the BMI decrease. CONCLUSIONS: Our results suggest that psychobehavioral and nutritional characteristics can be used as predictors of weight loss in response to a comprehensive weight management program including pharmacological treatment with sibutramine.
Introduction
The amount of weight loss in response to obesity treatment as well as weight loss maintenance are greatly influenced by genetic, metabolic, nutritional and neuropsychobehavioral factors. Energetic efficiency, sympathetic nervous system activity, fat oxidation and insulin sensitivity represent metabolic predictors of weight loss, especially in response to the short-term well-defined weight reduction program. 1 However, examination of such metabolic parameters requires special equipment that is not generally accessible.
Psychobehavioral factors play a crucial role in the adherence to weight control strategies that significantly influence weight loss maintenance. In contrast to metabolic parameters, psychobehavioral and nutritional characteristics can be easily obtained and analyzed. Previous studies revealed that scores on the Beck Depression Inventory (BDI) 2 were related to body weight loss during obesity treatment. [3] [4] [5] Eating related motivation is frequently evaluated by the Three Factor Eating Questionnaire also known as the Eating Inventory (EI), which was developed by
Stunkard and Messick. 6 The EI assesses dietary restraint, disinhibition and perceived hunger. Dietary restraint is a measure of self-imposed limitation of intake for weight control purposes; disinhibition assesses loss of control over eating in a variety of circumstances and hunger refers to the intensity of bodily sensations. The relationship between EI scores and weight change has been evaluated in the dietary treatment of obesity, 7 the treatment of severely obese patients by bariatric surgery 8 as well as in weight maintenance after diet-induced weight reduction. [9] [10] [11] Psychological and behavioral predictors of weight loss have also been evaluated in the context of pharmacological treatments for obesity, including fenfluramine, phentermine, mazindol and caffeine plus ephedrine, 12 usually administered as combined therapy (fenfluramine þ phentermine, fenfluramine þ mazindol). Baseline scores of two items of the EI, perceived hunger and dietary restraint, appeared important factors in the prediction of weight loss after 6 and 12 months of drug treatment. Patients who scored higher on dietary restraint and hunger at baseline were less likely to lose weight over the 6-month period, whereas only high hunger scoring at baseline predicted lower weight loss at 12 months. However, many of the drugs used in the study of Womble et al 12 have now been withdrawn from the pharmaceutical market.
No study of psychobehavioral and nutritional predictors of weight loss in response to sibutramine treatment has been conducted. Sibutramine is a potent reuptake inhibitor of both serotonin and noradrenaline. 13 The weight reducing effect of sibutramine in humans is obtained by a dual mechanism: reduction of energy intake due to increased satiety and decreased hunger, and prevention of the decline in energy expenditure that follows weight loss. 14 Sibutramine treatment results in consistent weight loss accompanied by improvement of obesity-related health risks. The STORM trial, a two-y clinical study, clearly demonstrated that sibutramine was efficient not only for increasing weight loss but also for facilitating weight loss maintenance. 15 In the STORM trial, only pretreatment body weight appeared an important independent predictor of 6-month weight loss and 24-month weight loss maintenance. The higher pretreatment weight was associated with a higher weight loss and weight loss maintenance. No psychobehavioral and nutritional characteristics were considered in this trial. In contrast, the weight loss induced in adolescents by 1-y treatment with sibutramine was not related to baseline characteristics, including the BMI. 16 The present study investigates whether the body mass index (BMI), psychobehavioral characteristics (Beck depression score, dietary restraint, disinhibition and perceived hunger), and nutritional measures (energy and macronutrient intake) at baseline were significant predictors of weight loss over 4-and 12-month periods in obese women enrolled in a weight reduction program, including a lowenergy diet, increased physical activity, cognitive behavior therapy and sibutramine. The relationship between the changes in psychobehavioral and nutritional factors and the decrease in BMI after 4 and 12 months of treatment was also investigated.
Patients and methods
In total, 90 obese women with a BMI of 30-45 kg/m 2 , aged 18-65 y, were recruited from the obesity outpatient clinics. The patients suffering from the following diseases were excluded from the trial: types 1 and 2 diabetes mellitus; endocrine diseases; peptic ulcer; uncontrolled hypertension; cardiovascular, cerebrovascular, hepatic and renal diseases; psychiatric illnesses and eating disorders. Contraindications also included lactation and pregnancy; weight change exceeding 5 kg or the use of antiobesity drugs in the previous 6 months; administration of serotonin reuptake inhibitors or monoamine oxidase inhibitors as well as medications affecting body weight or contraindicated with the use of sibutramine. All subjects signed informed consent forms. (5) . Attrition rate was the same in the two groups. Medication compliance was evaluated by counting the number of tablets returned at each monthly visit. In all subjects who were evaluated, the cumulative tablet consumption per month reached at least 93% of the dose prescribed.
All patients were prescribed a 5-6 MJ/day diet, with approximately 50-60% of the energy from carbohydrate, 15-20% from protein and 25-30% from fat. They were advised to distribute their daily intake over 4-5 meals. Patients were given detailed instructions for recording their dietary intake, that is, both amount and type of foods consumed. They also learned to use food composition tables that provided information about the calorie and macronutrient content of the most common Czech foods and that indicated, using a color code, each food's appropriateness in the weight management program (green colorFrecommended low-fat, low-energy items to be consumed frequently; orange colorFfood items with recommended moderate consumption; red colorFfood items that might be consumed exceptionally). One-week dietary records were analyzed at baseline and at months 4 and 12 using a computerized version of the Czech Nutrition File 'Vyziva'. This software includes almost 3000 food items and evaluates the intakes of energy, macronutrients and micronutrients.
Weight loss predictors in sibutramine treated obese women V Hainer et al All patients, regardless of their baseline physical activity level, were instructed to increase their routine daily physical activity. A 30 min walking, 5 days a week, was recommended as a minimum increase in daily physical activity. In daily physical activity records, patient reported time spent walking, cycling, swimming and performing other specified exercise. Only time spent walking was used in statistical analyses. In monthly check-ups, a physician together with a psychologist and a dietitian evaluated dietary and physical activity records and encouraged changes in lifestyle according to cognitive behavioral modification techniques.
The BDI and the EI were filled out at baseline and at months 4 and 12.
Body weight, waist circumference, sagittal diameter, subscapular and triceps skinfold thickness, pulse rate and blood pressure as well as occurrence of side effects were evaluated at each monthly visit. Height was measured at baseline and at 1-y follow-up. As expected only minor changes in height were recorded at 1-y follow-up. ECG was recorded and the levels of blood glucose, insulin, C-peptide, triglycerides, total cholesterol, HDL-cholesterol, uric acid were determined at screening and baseline assessments and at months 4, 8 and 12.
Statistical analysis
Results are presented as means7s.d. Differences in weight loss between the two groups of patients were compared using analysis of variance. A multiple regression model was chosen for prediction of change in BMI over 4-and 12-month periods. Initial BMI, mode of treatment (sibutramine vs placebo at 4 months, placebo and sibutramine or sibutramine throughout at 12 months), psychobehavioral (EI, BDI) and nutritional parameters (energy and macronutrient intake) were entered as predictors of change in BMI. Multiple regression analysis was also applied to investigate the relationships between the change in BMI (as dependent variable) and changes in all included psychobehavioral and nutritional parameters (as independent variables). Different transformations used in the same dependent variable were due to the fact that complete data were not available in all subjects. Hence, the data sets in individual models differed in data distribution and the different optimal transformations were compared. In the backward stepwise regression, Fisher's statistic 43 was chosen as a selection criterion. Statistica (version 6.0, Statsoft Inc., Tulsa, OK, USA) software and NCSS 2000 statistical software (Number Cruncher Statistical Systems, Kaysville, UT, USA) were used for the analysis.
Results
As shown in Figure 1 , body weight significantly decreased in both the placebo and sibutramine groups at month 4. Weight loss in the sibutramine group was significantly higher than that in the placebo group (9.0 vs 4.9 kg, Po0.001). At month 12, a significant (Po0.001) body weight loss vs baseline values was demonstrated in both the sibutramine and placeboFsibutramine groups. Significant decreases were also demonstrated for BMI and waist circumference (data not shown), whereas nonsignificant changes were observed in systolic and diastolic blood pressure and heart rate. Sibutramine induced a significant decline in plasma triglycerides and atherogenic index. Occurrence of side effects during the trial was rare in both groups of patients, except for dry mouth, which was reported more frequently in the sibutramine group than in the placebo group (20.0 vs 5.7%, P ¼ 0.027).
As shown in Figure 2 , significant changes in all EI parameters and in BDI score were demonstrated as a result of sibutramine treatment at month 4. Restraint increased while disinhibition and hunger decreased. Changes in all three items of the EI at month 4 were significantly more pronounced in the sibutramine treated than in the placebo treated group. The change in BDI score at month 4 was not different between the two groups.
From the beginning to the end of the trial, the mean reported daily energy intake decreased by 1729 kJ, that is, by 23% (from 7530 to 5801 kJ, Po0.001). The decline in energy intake during the initial 4-month period was larger in sibutramine than in placebo treated patients, but not significantly so. Reported fat intake decreased from 62.9 to 47.7 g per day (Po0.001) and percentage of energy consumed as fat declined from 32.1 to 28.9% (P ¼ 0.004). In spite of a decrease in the reported amount of protein consumed (from 64.0 to 54.3 g/day, P ¼ 0.001), the percentage of energy obtained from protein significantly increased during the trial (from 14.7 to 16.1%, P ¼ 0.006). Weight loss predictors in sibutramine treated obese women V Hainer et al
The increase in reported daily walking time during the initial 4-month period was significantly higher in the sibutramine than in the placebo group (175 min vs 80 min/week, P ¼ 0.017).
The multiple regression analysis of the relations between BMI loss after 4-month treatment and initial BMI, mode of treatment and baseline psychobehavioral and nutritional indices is shown in Table 1 . BMI loss at month 4 was significantly influenced by the mode of treatment and initial BMI, whereas a backward stepwise regression revealed a borderline negative relationship with baseline restraint score. These predictive variables accounted for 30.8% of the variance in BMI decrease at month 4. Baseline values for BMI, depression score, restraint score and energy intake predicted the decrease in BMI after the 12-month treatment accounting for 43.8% of the variance in the change in BMI (Table 2 ). However, if the decrease in BMI in response to the 4-month treatment was added to baseline parameters, the decrease in BMI at month 12 was mainly predicted by BMI decrease at month 4, whereas intial BMI, mode of treatment and baseline carbohydrate consumption appeared as additional significant predictors (Table 3) . This model accounted for 75.9% of the variance in BMI decline at month 12.
The decrease in BMI at month 4 was related to mode of treatment as well as to changes in restraint and disinhibition scores and in protein and fat intakes. Table 4 presents the regression parameters. These variables explained 56.6% of the variance in the change in BMI at month 4. When relationships between the decrease of BMI and changes in all included psychobehavioral and nutritional parameters were examined at month 12, a decrease in the disinhibition score remained the sole significant factor associated with the BMI decrease, explaining 29.3% of the total variation in BMI decrease at month 12 (Table 5 ). When the changes in BMI and all psychobehavioral and nutritional parameters at month 4 were related to the BMI loss after the 12-month treatment, the decreases in BMI and energy intake at month 4 remained significant predictors of the BMI change at month 12, accounting for 66.2% of variance in BMI change (not shown).
Discussion
Previous studies demonstrated that the initial response to drug treatment is a good predictor of long-term efficacy of the pharmacotherapy of obesity. 17, 18 Various anthropometric, metabolic and psychobehavioral parameters have been examined as predictors of weight loss and weight loss maintenance. Baseline body weight, mode of treatment and age explained only 9% of the variation in 24-month weight change in the STORM study. 19 Body weight or BMI at baseline predicted weight loss in several other studies on weight management. 10, 12 In the STORM study, 19 baseline body weight, sex, age, resting metabolic rate, smoking history, previous attempts to lose weight and age of onset of obesity were included as predictors of weight change but psychobehavioral and nutritional parameters were not taken into account. The main aim of our study was to evaluate whether certain psychobehavioral and nutritional parameters, besides the Figure 2 Effect of sibutramine and placebo on the BDI and EI scores. Striped and dark columns with error bars represent mean scores with SEM in placebo-and in sibutramine-treated groups, respectively. *Po0.05, ***Po0.001 for differences between month 0 and months 4 and 12; þ Po0.05, þ þ Po0.01 for differences between sibutramine and placebo.
Weight loss predictors in sibutramine treated obese women V Hainer et al baseline BMI, could predict weight loss in response to a weight management program including sibutramine. Another purpose of this study was to reveal associations between the sibutramine-associated changes in psychobehavioral and nutritional indexes and weight loss over 4-and 12-month periods of treatment.
Total weight loss at 1-y follow-up was not significantly different between patients receiving 8 and 12 months of sibutramine. This lack of significant difference between the two groups of patients is not surprising as most studies with antiobesity drugs including those with sibutramine and orlistat demonstrated that the maximum weight loss in response to drug treatment is achieved after 6-8 months whereas after 12-16 months of treatment, minor weight regain usually occurs. 15, 20 A period of 6-8 months is sufficient time to induce the maximum weight loss that can be obtained from the correction of regulatory or metabolic abnormalities by currently available antiobesity drugs. This is the reason why the mode of treatment disappeared as a predictor of weight loss in our 12-months analysis. Our study agrees with 2-y studies of the antiobesity drug orlistat, which demonstrated comparable weight loss in patients treated with orlistat during the whole-study period and in those treated with orlistat during the second year only. Weight loss predictors in sibutramine treated obese women V Hainer et al
20,21
The BMI decrease at month 4, during the placebo controlled period, was influenced by the mode of treatment and intial BMI as well as by baseline restraint score. As expected, sibutramine treatment predicted a greater decrease in BMI. Dietary restraint affected the weight loss both at months 4 and 12. Patients with higher dietary restraint at baseline were less likely to lose weight at both 4-and 12-month follow-up. Similar associations of dietary restraint with weight loss were demonstrated previously. 7, 8, 10, 12 Negative correlation between weight loss and baseline dietary restraint was demonstrated over a 5-6 month period of dietary treatment, 7 over both 6-and 12-month periods of drug treatment 12 and over a 1-y period after gastric banding. 8 In several studies, higher restraint scores were associated with lower body weight 7, 22, 23 and with better outcome in weight management program. [24] [25] [26] It could be hypothesized that our patients with higher levels of dietary restraint at baseline represented subjects who had been dieting and perhaps achieved some weight loss before the trial started. Owing to this likely pretrial weight suppression, these patients did not lose as much weight in response to treatment as the patients with initially low level of dietary Weight loss predictors in sibutramine treated obese women V Hainer et al restraint, who increased their restraint during the trial period.
Besides initial BMI and dietary restraint, depression score and total energy and protein intake at baseline accounted for 43.8% of the weight loss variance at month 12. High initial depression score and high-energy intake predicted lower weight loss at 12th month follow-up. In previous studies, depression appeared a negative prognostic marker for weight reduction. 3, 4 Obese patients with depression are at high risk of attrition in comprehensive obesity treatment, including VLCD and behavior therapy programs. 3 In the Diabetes Prevention Program, the weight loss self-efficacy correlated negatively with depression. 4 Moreover, depressed mood has been described as a trigger for dietary disinhibition, 26 which promotes weight gain. Weight loss in response to combined VLCD and behavior treatment is associated with a decrease in the BDI score. 5, 27, 28 However, Rolls et al 29 failed to show any significant change in the BDI in obese women after a 2-week treatment with sibutramine, although the drug did affect food intake. The BMI decrease over a 4-month period was significantly related to the mode of treatment and to changes in dietary restraint and disinhibition as well as to changes in protein and fat intake. These variables explained 56.6% of the variance in weight loss at month 4. Increases in dietary restraint and protein intake and decreases in disinhibition score and fat intake were associated with a higher weight loss. The success of weight loss maintenance has been shown to be dependent on an increase in dietary restraint during weight reduction phase. [9] [10] [11] In our previous study, 5 the weight loss in obese women in response to 4-week VLCD treatment combined with cognitive behavioral therapy was associated with a significant increase in restraint score and a significant decrease in disinhibition and hunger scores of the EI, as well as with a significant decrease in the Beck depression score.
It is not surprising that a decrease in fat intake was associated with weight loss as fat intake reduction plays an essential role in dietary weight management. 30, 31 The positive association between protein consumption and weight loss might be facilitated by both increased satiety and increased postprandial thermogenesis induced by protein intake. [32] [33] In our previous study, body weight loss of obese subjects during a 3-6 months weight management program was related to the increase in reported protein intake. 34 Westerterp-Plantenga et al 35 reported that a 20% increase in protein intake improved weight maintenance after weight loss in moderately obese subjects. An appropriate protein intake should be therefore recommended in weight management during both weight loss and weight maintenance periods. Ben-Menachem et al 36 searched for predictors of weight change in response to topiramate treatment of patients with epilepsy. In this study no dietary advice was given but dietary records were evaluated at baseline and after both 3 months and 1 y of drug treatment. At 3 months, energy intake was reduced by 186 kcal and weight change associated with topiramate treatment correlated with lower baseline energy intake, energy intake reduction as well as with higher baseline leptin and rT 3 levels. As in our study and in the STORM trial 19 with sibutramine, baseline BMI significantly predicted weight loss maintenance in topiramate treated patients; baseline BMI remained the only factor correlating with weight loss after 1 y treatment with topiramate. Another drug trial evaluated the EI scores in overweight men during a 6-week treatment with recombinant leptin and VLCD as well as after 8-week follow-up. 37 A period of 6-week treatment by leptin/VLCD, similarly to our 4-week VLCD trial, 5 lead to an increase in cognitive restraint score and to a significant decrease in both disinhibition and hunger scores. The decrease in hunger score during the leptin treatment was Weight loss predictors in sibutramine treated obese women V Hainer et al positively related to body weight loss. On the other hand, the increase in dietary restraint during the leptin treatment was inversely related to body weight regain after 8 weeks of follow-up. However, the decrease in disinhibition score during the treatment period positively correlated with the weight loss in the placebo group and not in the leptintreated group. 37 Among the recorded changes in behavioral and nutritional parameters over the study, our results revealed the unique role of change in disinhibition score, which remained the sole significant factor related to the BMI decrease at month 12. The association of sibutramine-induced weight loss with a decline in disinhibition might be related to the previously shown positive impact of sibutramine treatment on obesityrelated health risks. 15 
